<DOC>
	<DOCNO>NCT02237937</DOCNO>
	<brief_summary>The study evaluate ABCB1-genotype dependent efficacy quick dose-escalation strategy within 28 day treatment approve antidepressant know substrate P-glycoprotein , efflux pump blood-brain barrier express ABCB1 gene . Moreover , study evaluate ABCB1-genotype dependent side-effects approve antidepressant know substrate P-glycoprotein , efflux pump blood-brain barrier express ABCB1 gene .</brief_summary>
	<brief_title>Optimizing Antidepressant Treatment Genotype-dependent Adjustment Medication According ABCB1 Gene</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Trimipramine</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<criteria>Male female patient Age 18 80 year Inpatients DSMIV diagnosis Major Depression single episode recurrent moderate severe intensity without psychotic feature Inpatients DSMIV diagnosis bipolar disorder I II current episode depressive symptom moderate severe intensity without psychotic feature HAMD score time inclusion study â‰¥ 14 Patient already adjust one follow antidepressant dose still define normaldose : paroxetine &lt; 40 mg/d sertraline &lt; 100 mg/d citalopram &lt; 40 mg/d escitalopram &lt; 20 mg/d venlafaxine &lt; 225 mg/d amitriptyline &lt; 150 mg/d amitriptylinoxide &lt; 150 mg/d nortriptyline &lt; 150 mg/d trimipramine &lt; 150 mg/d Acute suicidality ( HAMD Item 3 score &gt; 2 ) Acute alcohol , hypnotic , analgesic psychopharmacological intoxication delirium Current alcohol dependence , dependency psychotropic substance Severe medical neurological disease : patient severe hepatic ( severe impairment liver function , cirrhosis liver ) , renal ( kidney malfunction ) , cardiovascular ( recent myocardial infarction , instable heart disease ) , neurological disease ( e.g . multiple sclerosis , Parkinson , dementia ) Patients incapable give informed consent Pregnant breastfeed woman Women reproductive age without effective contraception Simultaneous participation clinical trial participation clinical trial within 6 week start study Hypersensitivity study medication one ingredients medication Simultaneous treatment another antidepressant besides study medication ( exception : trazodone 75 mg/d , mirtazapine 15 mg/d , trimipramine 50 mg/d ) Simultaneous treatment mood stabilizer neuroleptic drug ( exception : quetiapine 50 mg/d , olanzapine 5 mg/d ) Exclusion criterion study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Depression , Affective Disorder</keyword>
</DOC>